Comparative incidence of adverse drug reaction during the first and subsequent year of antiretroviral therapy in a Nigerian HIV infected Cohort

被引:5
作者
Abah, Isaac O. [1 ]
Dayom, Wetkos D. [1 ]
Dangiwa, Dauda A. [1 ]
Aderemi-Williams, Roseline [2 ]
Anejo-Okopi, Joseph [3 ]
Agbaji, Oche O. [4 ]
Kanki, Phyllis [5 ]
Aguiyi, John C. [6 ]
机构
[1] Univ Jos, Dept Clin Pharm & Pharm Practice, Jos Univ Teaching Hosp, Jos, Nigeria
[2] Univ Lagos, Fac Pharm, Dept Clin Pharm & Biopharm, Idiaraba Campus, Lagos, Nigeria
[3] Univ Jos, Dept Microbiol, Jos, Nigeria
[4] Univ Jos, Dept Med, Jos Univ Teaching Hosp, Jos, Nigeria
[5] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA USA
[6] Univ Jos, African Ctr Excellence Phytomed Res & Dev, Jos, Nigeria
基金
美国国家卫生研究院;
关键词
Adverse drug events; antiretroviral therapy; drug toxicity; sub Saharan Africa; RISK-FACTORS; NEUROPSYCHIATRIC COMPLICATIONS; EFAVIRENZ; NEVIRAPINE; RASH; LIPODYSTROPHY; PREVALENCE;
D O I
10.4314/ahs.v21i3.10
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Despite close to two decades of antiretroviral therapy (ART) in Nigeria, data on late on-onset ART-associated adverse drug reactions (ADRs) are sparse. Objectives: To describe early and late-onset ADRs and compare their incidence in an outpatient HIV positive Cohort on ART. Method: We described the incidence of clinical ADRs identified and documented in an outpatient clinic cohort of HIV-positive patients treated between June 2004 and December 2015 at a tertiary health facility in Nigeria. Incidence rates of ADRs during the first and subsequent years of ART were compared. Results: of the 13,983 patients' data analyzed, 9317 were females (66%), and those in the age bracket of 25 to 45 years made up 78% of the studied population. During 52,411 person-years (py) of ART, 1485 incident ADRs were recorded; Incidence rate (IR) 28.3 (95% confidence interval [CI] 26.9:29.8) ADRs per 1000 person-years (py) of ART. The IR of ADRs was about two times higher in the first year of ART compared to subsequent years of treatment; crude incidence rate ratio (IRR) 1.77 (95% CI 1.59:1.97). Anemia, hypersensitivity reactions, and nervous system disorders had 7, 23, and 5 times higher incidence, respectively, in the first year of therapy, compared to subsequent years. Conclusion: The first year of ART is the period of highest risk of ADRs. Individual and programmatic treatment success in resource-limited settings requires strategies for early identification and management of ADR during the period of greatest risk of ADRs.
引用
收藏
页码:1027 / 1039
页数:13
相关论文
共 46 条
[21]   Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients [J].
Hawkins, T ;
Geist, C ;
Young, B ;
Giblin, A ;
Mercier, RC ;
Thornton, K ;
Haubrich, R .
HIV CLINICAL TRIALS, 2005, 6 (04) :187-196
[22]   Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database [J].
Heath, KV ;
Hogg, RS ;
Chan, KJ ;
Harris, M ;
Montessori, V ;
O'Shaughnessy, MV ;
Montaner, JSG .
AIDS, 2001, 15 (02) :231-239
[23]  
Keiser O, 2007, ANTIVIR THER, V12, P1157
[24]   Adverse drug reactions to antiretroviral therapy during the early art period at a tertiary hospital in Ghana [J].
Lartey, Margaret ;
Asante-Quashie, Abena ;
Essel, Ama ;
Kenu, Ernest ;
Ganu, Vincent ;
Neequaye, Alfred .
PAN AFRICAN MEDICAL JOURNAL, 2014, 18
[25]   Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection [J].
Lundgren, Jens D. ;
Babiker, Abdel G. ;
Gordin, Fred ;
Emery, Sean ;
Sharma, Shweta ;
Avihingsanon, An-Chalee ;
Cooper, David A. ;
Faetkenheuer, Gerd ;
Llibre, Josep M. ;
Moli-Na, Jean-Michel ;
Munderi, Paula ;
Schechter, Mauro ;
Wood, Robin ;
Klingman, Karin L. ;
Collins, Simon ;
Lane, H. Clifford ;
Phillips, Andrew N. ;
Neaton, James D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (09) :795-807
[26]   Efavirenz versus nevirapine in current clinical practice: A prospective, open-label observational study [J].
Manfredi, R ;
Calza, L ;
Chiodo, F .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (05) :492-502
[27]   Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash [J].
Manosuthi, W. ;
Thongyen, S. ;
Chumpathat, N. ;
Muangchana, K. ;
Sungkanuparph, S. .
HIV MEDICINE, 2006, 7 (06) :378-382
[28]   An assessment of adverse drug reactions among HIV positive patients receiving antiretroviral treatment in South Africa [J].
Masenyetse, Lieketseng J. ;
Manda, Samuel O. M. ;
Mwambi, Henry G. .
AIDS RESEARCH AND THERAPY, 2015, 12
[29]  
Mehta UC, 2011, CME, V29, P247
[30]  
Mudzviti T., 2015, Pharmacology and Pharmacy, V6, P201, DOI 10.4236/pp.2015.63021